In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 3.31 million shares changing hands with its beta currently measuring 2.16. Company’s recent per share price level of $0.73 trading at $0.05 or 6.62% at ring of the bell on the day assigns it a market valuation of $185.38M. That closing price of ADAP’s stock is at a discount of -180.82% from its 52-week high price of $2.05 and is indicating a premium of 42.47% from its 52-week low price of $0.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.84 million shares which gives us an average trading volume of 1.46 million if we extend that period to 3-months.
For Adaptimmune Therapeutics Plc ADR (ADAP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.89. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Upright in the green during last session for gaining 6.62%, in the last five days ADAP remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $0.73 price level, adding 0.12% to its value on the day. Adaptimmune Therapeutics Plc ADR’s shares saw a change of -8.58% in year-to-date performance and have moved 9.07% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of 2.91% in past 30-days. Number of shares sold short was 5.35 million shares which calculate 4.71 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 75.67% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -36.99% in reaching the projected high whereas dropping to the targeted low would mean a loss of -36.99% for stock’s current value.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Statistics highlight that Adaptimmune Therapeutics Plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -28.22% of value to its shares in past 6 months, showing an annual growth rate of 77.78% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 204.90% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 8.83M for the same. And 3 analysts are in estimates of company making revenue of 6.3M in the next quarter. Company posted 231k and 5.68M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.30% during past 5 years.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Insiders are in possession of 0.38% of company’s total shares while institution are holding 60.27 percent of that, with stock having share float percentage of 60.49%. Investors also watch the number of corporate investors in a company very closely, which is 60.27% institutions for Adaptimmune Therapeutics Plc ADR that are currently holding shares of the company. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ADAP for having 38.97 million shares of worth $38.0 million. And as of 2024-06-30, it was holding 16.1135 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 27.4 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.3299 of outstanding shares, having a total worth of $26.72 million.
On the other hand, SPDR Portfolio Developed World ex-US ETF and SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 246.31 shares of worth $0.18 million or 0.10% of the total outstanding shares. The later fund manager was in possession of 150.61 shares on Aug 31, 2024 , making its stake of worth around $0.11 million in the company or a holder of 0.06% of company’s stock.
